Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems - The taliglucerase alfa story

Bonita Rup, Sari Alon, Bat Chen Amit-Cohen, Einat Brill Almon, Raul Chertkoff, Yoram Tekoah, Pauline M. Rudd

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Plants are a promising alternative for the production of biotherapeutics. Manufacturing in-planta adds plant specific glycans. To understand immunogenic potential of these glycans, we developed a validated method to detect plant specific glycan antibodies in human serum. Using this assay, low prevalence of pre-existing anti-plant glycan antibodies was found in healthy humans (13.5%) and in glucocerebrosidase-deficient Gaucher disease (GD) patients (5%). A low incidence (9% in naïve patient and none in treatment experienced patients) of induced anti-plant glycan antibodies was observed in GD patients after up to 30 months replacement therapy treatment with taliglucerase alfa, a version of human glucocerebrosidase produced in plant cells. Detailed evaluation of clinical safety and efficacy endpoints indicated that anti-plant glycan antibodies did not affect the safety or efficacy of taliglucerase alfa in patients. This study shows the benefit of using large scale human trials to evaluate the immunogenicity risk of plant derived glycans, and indicates no apparent risk related to anti-plant glycan antibodies.

Original languageEnglish
Article numbere0186211
JournalPLoS ONE
Volume12
Issue number10
DOIs
StatePublished - 1 Oct 2017
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (all)
  • Agricultural and Biological Sciences (all)
  • General

Fingerprint

Dive into the research topics of 'Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems - The taliglucerase alfa story'. Together they form a unique fingerprint.

Cite this